Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,496 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patch 2 Clear all
Completed Phase 4 Interventional Results available

Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis

NCT01960257
View directory record Official record
Conditions
Tuberculosis
Interventions
Digital Health Feedback System, SOC DOT
Device · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Phase 4 Interventional Results available

A Smoking Cessation Intervention for Yale Dining Employees

NCT02562521
View directory record Official record
Conditions
Smoking Cessation
Interventions
Contingency management, Nicotine replacement therapy, Varenicline, Additional behavioral support
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Phase 4 Interventional Results available

A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers

NCT01553084
View directory record Official record
Conditions
Smoking Cessation, Smoking, Nicotine Dependence
Interventions
Varenicline, Nicotine lozenge, Nicotine Patch
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Not applicable Interventional

Study of New Software Used During Ablations

NCT01906021
View directory record Official record
Conditions
Liver Cancer, Neoplasms, Liver, Hepatic Neoplasms, Hepatic Cancer
Interventions
CT/CBCT thermometry method, Ablation Probe
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

NCT03224598
View directory record Official record
Conditions
Dermatosis Papulosa Nigra
Interventions
A-101 Topical Solution 40%
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 30, 2026, 10:07 AM EDT
Terminated Early Phase 1 Interventional

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

NCT00499733
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 30, 2026, 10:07 AM EDT
Suspended Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia

NCT05259306
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Insightec Exablate Neuro MR-guided focused ultrasound transducer
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 30, 2026, 10:07 AM EDT
Terminated Phase 2 Interventional Results available

Prevention of Restenosis Following Revascularization

NCT00518284
View directory record Official record
Conditions
Vascular Disease, Peripheral
Interventions
Nanoparticle Paclitaxel
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Sacramento, California • Gainsville, Florida • Davenport, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

NCT00061893
View directory record Official record
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 30, 2026, 10:07 AM EDT
Completed No phase listed Observational

Evaluating for Contact Allergies in Patients With Chronic Urticaria

NCT00868036
View directory record Official record
Conditions
Urticaria, Patch Testing, Dermatitis, Allergy, Contact Sensitization
Interventions
Patch Testing
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 30, 2026, 10:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia

NCT06763536
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Carbon Monoxide Measurement, Nicotine Lozenge, Oral Nicotine Pouch, Nicotine Patch, Survey Administration, Check-in Phone Calls
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Not applicable Interventional

Development of a Tailored Smoking Cessation Program for Individuals With HIV Infection in Washington, D.C.

NCT04594109
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Tailored behavioral counseling, Standard of Care
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 30, 2026, 10:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

NCT01217411
View directory record Official record
Conditions
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Embedding Comprehensive Smoking Cessation Programs Into Community Clinics

NCT04717544
View directory record Official record
Conditions
Smoking Cessation
Interventions
Intervention Arm
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 30, 2026, 10:07 AM EDT
Not listed Phase 2 Interventional

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

NCT06409195
View directory record Official record
Conditions
Non-Melanoma Skin Cancers
Interventions
SM-020 1% Gel
Drug
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 30, 2026, 10:07 AM EDT
Recruiting Phase 2 Interventional

Combined Immunotherapies in Metastatic ER+ Breast Cancer

NCT04563507
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions), Letrozole 2.5Mg Tab, Palbociclib 125mg
Radiation · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 10:07 AM EDT
Terminated Phase 1 Interventional

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

NCT00977145
View directory record Official record
Conditions
Melanoma
Interventions
A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 30, 2026, 10:07 AM EDT
Active, not recruiting Not applicable Interventional

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NCT03033992
View directory record Official record
Conditions
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
Device · Combination Product
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old

NCT01574612
View directory record Official record
Conditions
Herpes Labialis
Interventions
acyclovir/hydrocortisone cream
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Opa-locka, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 30, 2026, 10:07 AM EDT
Terminated No phase listed Observational

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

NCT01156298
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

NCT02937558
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Glucagon, Placebo
Drug · Other
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
Up to 12 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

NCT03714828
View directory record Official record
Conditions
Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma, Cutaneous Tumor, Skin Cancer, Squamous Cell, Lesion Skin
Interventions
Injection of TVEC into target lesions - week 1-2, Injection of TVEC into target lesions 3wks after 1st injection, Injection of TVEC into target lesions 2wks after 2nd injection, Injection of TVEC into target lesions 2wks after 3rd injection
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

NCT00796289
View directory record Official record
Conditions
Infertility
Interventions
GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 38 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Oct 30, 2026, 10:07 AM EDT
Completed Not applicable Interventional Results available

Nicotine and Behavior in Adult ADHD

NCT00573248
View directory record Official record
Conditions
ADHD
Interventions
Nicotine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2011 · Synced Oct 30, 2026, 10:07 AM EDT